Evommune, Inc.
EVMN
$20.49
$0.301.49%
NYSE
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
1/19/2026
-
MarketBeat
6/2/2026
-
TipRanks Financial Blog
5/25/2026
-
The Cerbat Gem
5/10/2026
-
MarketBeat
5/9/2026
-
The Cerbat Gem
5/9/2026
-
Simply Wall St
5/7/2026
-
TipRanks Financial Blog
5/7/2026
-
Business Wire
5/6/2026
-
TipRanks Financial Blog
5/2/2026
-
MarketBeat
5/1/2026
-
MarketBeat
5/1/2026
-
Zolmax
4/30/2026
-
TipRanks Financial Blog
4/30/2026
-
MarketBeat
4/28/2026
-
MarketBeat
4/25/2026
-
TipRanks Financial Blog
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Edwards Lifesciences (EW)
4/24/2026
-
TipRanks Financial Blog
4/22/2026
-
Simply Wall St
4/17/2026
-
TipRanks Financial Blog
4/14/2026
-
SeekingAlpha
4/14/2026
-
Seeking Alpha: Transcripts
4/13/2026
-
TipRanks Financial Blog
4/10/2026
-
MarketBeat
4/10/2026
-
MarketBeat
4/10/2026
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, May 7, 2026
Period Date
Tuesday, March 31, 2026
Next Filing
Week of Jul 13 and 17 (est)
Price History
Beta
--
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
925 247 4481
Address
1841 Page Mill Road
Palo Alto, CA 94304
Palo Alto, CA 94304
Country
Year Founded
Business Description
Sector
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial...
more